

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Withdrawn) An isolated polypeptide, comprising at least an immunogenic portion of a lung tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(a) sequences recited in SEQ ID NOs: 218-222, 224-226, 249, 250, 253, 256, 266, 276, 277, 282, 285, 293, 295, 298, 299, 301, 304, 306, 316, 321, 326, 333, 336, 337, 342, 353, 359, 361, 364, 369, 372, 373, 377, 379, 386, 390, 392 and 440;

(b) sequences that hybridize to a sequence recited in any one of SEQ ID NOs: 218-222, 224-226, 249, 250, 253, 256, 266, 276, 277, 282, 285, 293, 295, 298, 299, 301, 304, 306, 316, 321, 326, 333, 336, 337, 342, 353, 359, 361, 364, 369, 372, 373, 377, 379, 386, 390, 392 and 440 under moderately stringent conditions; and

(c) complements of sequences of (a) or (b).

2. (Withdrawn) An isolated polypeptide according to claim 1, wherein the polypeptide comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOs: 218-222, 224-226, 249, 250, 253, 256, 266, 276, 277, 282, 285, 293, 295, 298, 299, 301, 304, 306, 316, 321, 326, 333, 336, 337, 342, 353, 359, 361, 364, 369, 372, 373, 377, 379, 386, 390, 392 and 440 or a complement of any of the foregoing polynucleotide sequences.

3. (Withdrawn) An isolated polypeptide comprising a sequence recited in any one of SEQ ID NO: 391, 393, 395, 397, 421 and 425-427.

4. (Currently Amended) An isolated polynucleotide, ~~encoding at least 15 amino acid residues of a lung tumor protein, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen specific antisera is not substantially diminished, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide comprising a sequence recited in any one of SEQ ID NOs: 218-222, 224-226, 249, 250, 253, 256, 266, 276, 277, 282, 285, 293, 295, 298, 299, 301, 304, 306, 316, 321, 326, 333, 336, 337, 342, 353, 359, 361, 364, 369, 372, 373, 377, 379, 386, 390, 392 and 440, or a complement of any of the foregoing sequences~~comprising at least 415 contiguous nucleotides of the sequence recited in SEQ ID NO:440.

5. (Currently Amended) An isolated polynucleotide, ~~encoding a lung tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide comprising a sequence recited in any one of SEQ ID NOs: 218-222, 224-226, 249, 250, 253, 256, 266, 276, 277, 282, 285, 293, 295, 298, 299, 301, 304, 306, 316, 321, 326, 333, 336, 337, 342, 353, 359, 361, 364, 369, 372, 373, 377, 379, 386, 390, 392 and 440 or a complement of any of the foregoing sequences~~comprising a sequence having at least 90 percent identity to the sequence recited in SEQ ID NO:440.

6. (Currently Amended) An isolated polynucleotide, comprising a sequence ~~recited in any one of SEQ ID NOs: 218-222, 224-226, 249, 250, 253, 256, 266, 276, 277, 282, 285, 293, 295, 298, 299, 301, 304, 306, 316, 321, 326, 333, 336, 337, 342, 353, 359, 361, 364, 369, 372, 373, 377, 379, 386, 390, 392 and 440.~~

7. (Currently Amended) An isolated polynucleotide, comprising a sequence that hybridizes to a sequence recited in ~~any one of SEQ ID NOs: 218-222, 224-226, 249, 250, 253, 256, 266, 276, 277, 282, 285, 293, 295, 298, 299, 301, 304, 306, 316, 321, 326, 333, 336, 337, 342, 353, 359, 361, 364, 369, 372, 373, 377, 379, 386, 390, 392 and 440~~ under moderately stringent conditions.

8. (Original) An isolated polynucleotide complementary to a polynucleotide according to any one of claims 4-7.

9. (Withdrawn) An expression vector, comprising a polynucleotide according to any one of claims 4-8.

10. (Withdrawn) A host cell transformed or transfected with an expression vector according to claim 9.

11. (Withdrawn) An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a lung tumor protein that comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOs: 218-222, 224-226, 249, 250, 253, 256, 266, 276, 277, 282, 285, 293, 295, 298, 299, 301, 304, 306, 316, 321, 326, 333, 336, 337, 342, 353, 359, 361, 364, 369, 372, 373, 377, 379, 386, 390, 392 and 440 or a complement of any of the foregoing polynucleotide sequences.

12. (Withdrawn) A fusion protein, comprising at least one polypeptide according to claim 1.

13. (Withdrawn) A fusion protein according to claim 12, wherein the fusion protein comprises an expression enhancer that increases expression of the fusion protein in a host cell transfected with a polynucleotide encoding the fusion protein.

14. (Withdrawn) A fusion protein according to claim 12, wherein the fusion protein comprises a T helper epitope that is not present within the polypeptide of claim 1.

15. (Withdrawn) A fusion protein according to claim 12, wherein the fusion protein comprises an affinity tag.

16. (Canceled)

17. (Withdrawn) A pharmaceutical composition, comprising a physiologically acceptable carrier and at least one component selected from the group consisting of:

- (a) a polypeptide according to claim 1;
- (b) a polynucleotide according to claim 4;
- (c) an antibody according to claim 11;
- (d) a fusion protein according to claim 12; and
- (e) a polynucleotide according to claim 16.

18. (Withdrawn) An immunogenic composition comprising an immunostimulant and at least one component selected from the group consisting of:

- (a) a polypeptide according to claim 1;
- (b) a polynucleotide according to claim 4;
- (c) an antibody according to claim 11;
- (d) a fusion protein according to claim 12; and
- (e) a polynucleotide according to claim 16.

19. (Withdrawn) An immunogenic composition according to claim 18, wherein the immunostimulant is an adjuvant.

20. (Withdrawn) An immunogenic composition according to claim 18, wherein the immunostimulant induces a predominantly Type I response.

21. (Withdrawn) A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a pharmaceutical composition according to claim 17.

22. (Withdrawn) A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of an immunogenic composition according to claim 18.

23. (Withdrawn) A pharmaceutical composition comprising an antigen-presenting cell that expresses a polypeptide according to claim 1, in combination with a pharmaceutically acceptable carrier or excipient.

24. (Withdrawn) A pharmaceutical composition according to claim 23, wherein the antigen presenting cell is a dendritic cell or a macrophage.

25. (Withdrawn) An immunogenic composition comprising an antigen-presenting cell that expresses a polypeptide comprising at least an immunogenic portion of a lung tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(a) sequences recited in SEQ ID NOs: 217-390, 392, 394, 396, 398-420, 422-424, 428-433 and 440;

(b) sequences that hybridize to a sequence recited in any one of SEQ ID NOs: 217-390, 392, 394, 396, 398-420, 422-424, 428-433 and 440 under moderately stringent conditions; and

(c) complements of sequences of (i) or (ii);
in combination with an immunostimulant.

26. (Withdrawn) An immunogenic composition according to claim 25, wherein the immunostimulant is an adjuvant.

27. (Withdrawn) An immunogenic composition according to claim 25, wherein the immunostimulant induces a predominantly Type I response.

28. (Withdrawn) An immunogenic composition according to claim 25, wherein the antigen-presenting cell is a dendritic cell.

29. (Withdrawn) A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of an antigen-presenting cell that expresses a polypeptide comprising at least an immunogenic portion of a lung tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(a) sequences recited in SEQ ID NOs: 217-390, 392, 394, 396, 398-420, 422-424, 428-433 and 440;

(b) sequences that hybridize to a sequence recited in any one of SEQ ID NOs: 217-390, 392, 394, 396, 398-420, 422-424, 428-433 and 440 under moderately stringent conditions; and

(c) complements of sequences of (i) or (ii);

and thereby inhibiting the development of a cancer in the patient.

30. (Withdrawn) A method according to claim 29, wherein the antigen-presenting cell is a dendritic cell.

31. (Withdrawn) A method according to any one of claims 21, 22 and 29, wherein the cancer is lung cancer.

32. (Withdrawn) A method for removing tumor cells from a biological sample, comprising contacting a biological sample with T cells that specifically react with a lung tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

- (i) polynucleotides recited in any one of SEQ ID NOs: 217-390, 392, 394, 396, 398-420, 422-424, 428-433 and 440; and
- (ii) complements of the foregoing polynucleotides;

wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of cells expressing the antigen from the sample.

33. (Withdrawn) A method according to claim 32, wherein the biological sample is blood or a fraction thereof.

34. (Withdrawn) A method for inhibiting the development of a cancer in a patient, comprising administering to a patient a biological sample treated according to the method of claim 32.

35. (Withdrawn) A method for stimulating and/or expanding T cells specific for a lung tumor protein, comprising contacting T cells with at least one component selected from the group consisting of:

(a) polypeptides comprising at least an immunogenic portion of a lung tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) sequences recited in SEQ ID NOs: 217-390, 392, 396, 398-420, 422-424, 428-433 and 440;

(ii) sequences that hybridize to a sequence recited in any one of SEQ ID NOs: 217-390, 392, 396, 398-420, 422-424, 428-433 and 440 under moderately stringent conditions; and

(iii) complements of sequences of (i) or (ii);

(b) polynucleotides encoding a polypeptide of (a); and

(c) antigen presenting cells that express a polypeptide of (a);

under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

36. (Withdrawn) An isolated T cell population, comprising T cells prepared according to the method of claim 35.

37. (Withdrawn) A method for determining the presence or absence of a cancer in a patient, comprising the steps of:

(a) contacting a biological sample obtained from a patient with a binding agent that binds to a lung tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOs: 217-390, 392, 394, 396, 398-420, 422-424, 428-433 and 440 or a complement of any of the foregoing polynucleotide sequences;

(b) detecting in the sample an amount of polypeptide that binds to the binding agent; and

(c) comparing the amount of polypeptide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient.

38. (Withdrawn) A method according to claim 37, wherein the binding agent is an antibody.

39. (Withdrawn) A method according to claim 38, wherein the antibody is a monoclonal antibody